# Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)

> **NCT00079482** · PHASE2 · COMPLETED · sponsor: **Cephalon** · enrollment: 224 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** CEP-701
- **DRUG:** high-dose cytarabine
- **DRUG:** Mitozantrone, Etoposide, Cytarabine (combination Chemotherapy)

## Key facts

- **NCT ID:** NCT00079482
- **Lead sponsor:** Cephalon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2009-03
- **Final completion:** 2010-01
- **Target enrollment:** 224 (ACTUAL)
- **Last updated:** 2016-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00079482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00079482, "Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00079482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*